Gene or Genome
Neurogene Details New Safety Measures After Young Patient’s Death in Rett Syndrome AAV Gene Therapy Trial
Neurogene; AAV gene therapy; Rett syndrome; NGN-401; ASGCT; safety measures; HLH; clinical trial; MECP2 gene; FDA; dose adjustment
Incyte’s Zynyz Secures FDA Approval for Anal Cancer After Previous Rejection
Incyte; Zynyz; retifanlimab; FDA approval; anal cancer; PD-1 inhibitor; first-line therapy; immunotherapy; clinical trial; POD1UM-303; combination chemotherapy
Bluebird Private Equity Buyout Boosts Upfront Cash for Shareholders
Bluebird; private equity buyout; shareholders; upfront cash; Carlyle; SK Capital; contingent value right; CVR; buyout terms; merger
GSK Acquires Phase III-Ready Liver Drug Efimosfermin for Up to $2B to Enter MASH Arena
GSK; Boston Pharmaceuticals; efimosfermin alfa; Phase III; liver disease; MASH; SLD; drug acquisition; FGF21 analog
GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results
GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival
Revolutions KRAS drugs appear competitive in several lung cancer settings
KRAS G12C inhibitors, non-small cell lung cancer (NSCLC), targeted therapy, sotorasib (Lumakras), adagrasib (Krazati), biomarker testing, Revolution Medicines
Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit
Vaccines, Urinary hesitation, Offit, cynicism, Misinformation, Immune response, Paul Offit, mandates
Lilly backs $65M raise for biotech plumbing the ‘dark genome’ with AI
Haya, Eli Lilly, Genome, Long Intergenic Non-Protein Coding RNA, Obesity, Aortic Valve Insufficiency, Eli, Dark color
Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides
MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1
CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%
Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes